May 29, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 04, 2020
Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020
Apr 29, 2020
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
Mar 12, 2020
Marker Therapeutics Reports Full Year 2019 Operating and Financial Results
Mar 02, 2020
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
Feb 11, 2020
Marker Therapeutics Announces Update to its Clinical Program in AML
Nov 25, 2019
Marker Therapeutics to Present at Two Upcoming Investor Conferences
Nov 12, 2019
Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results
Nov 11, 2019
Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019
Aug 15, 2019
Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs
Aug 06, 2019
Marker Therapeutics Appoints Steve Elms to its Board of Directors
Jul 20, 2019
Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
Jul 17, 2019
Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma
Jun 20, 2019
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
May 21, 2019
Marker Therapeutics to Present at Two Upcoming Investor Conferences
May 07, 2019
Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
Mar 28, 2019
Marker Therapeutics Provides Business and Clinical Update
Mar 18, 2019
Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
Feb 25, 2019
Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
Feb 21, 2019
Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award